Disruption of hSWI/SNF complexes in T cells by WAS mutations distinguishes X-linked thrombocytopenia from Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome (WAS), an immunodeficiency disorder, and X-linked thrombocytopenia (XLT), a bleeding disorder, both arise from nonsynonymous mutations in WAS, which encodes a hematopoietic-specific WASp. Intriguingly, XLT evolves into WAS in some patients but not in others; yet the biological basis for this cross-phenotype (CP) effect remains unclear. Using human T-helper (T-H) cells expressing different disease-causing WAS mutations, we demonstrated that hSWI/SNF-like complexes require nuclear WASp to execute their chromatin-remodeling activity at promoters of WASp-target, immune function genes during T(H)1 differentiation. Hot-spot WAS mutations Thr45Met and Arg86Cys, which result in XLT-to-WAS disease progression, impair recruitment of hBRM-but not BRG1-enriched BAF complexes to IFNG and TBX21 promoters. Moreover, promoter enrichment of histone H2A.Z and its catalyzing enzyme EP400 are both impaired. Consequently, activation of Notch signaling, a hBRM-regulated event, and its downstream effector NF-kappa B are both compromised, along with decreased accessibility of nucleosomal DNA and inefficient transcription-elongation of WASp-target T(H)1 genes. In contrast, patient mutations Ala236Gly and Arg477Lys that manifest in XLT without progressing toWAS do not disrupt chromatin remodeling or transcriptional reprogramming of T(H)1 genes. Our study defines an indispensable relationship between nuclear-WASp- and hSWI/SNF-complexes in gene activation and reveals molecular distinctions in T-H cells that might contribute to disease severity in the XLT/WAS clinical spectrum.